Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China.
Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China; No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, China.
Phytomedicine. 2022 Aug;103:154229. doi: 10.1016/j.phymed.2022.154229. Epub 2022 Jun 2.
Modified Jianpi Yangzheng decoction (mJPYZ), as an empirical decoction of Traditional Chinese medicine has been shown significantly to prolong the survival of patients with advanced stage gastric cancer. Pyruvate kinase M2 (PKM2), has attracted attention for its important role on cellular aerobic glycolysis, however, few studies focus on PKM2 non-metabolic roles in tumor progression.
Our study aimed to investigate the potential role of gastric cancer exosomes containing PKM2 in regulating tumor-associated macrophages (TAM) and the mechanism of mJPYZ against gastric cancer.
Colony Formation Assay, flow cytometry and TUNEL staining were employed to estimate the effect of mJPYZ on gastric cancer in tumor-bearing mice and cells. Western blot analyzed apoptosis-related protein expression changes. Network pharmacology and bioinformatics predicted potential exosomes modulation of mJPYZ in gastric cancer. Exosomes were isolated and co-cultured with TAM. Diff-Quik Staining observed the TAM morphological changes when incubating with gastric cancer cells exosomes. Flow cytometry and immunofluorescence were performed to demonstrate whether exosomes PKM2 involved in TAM polarization.
mJPYZ induced apoptosis of gastric cancer cells by targeting PKM2 and downregulating PI3K/Akt/mTOR axis in vivo and in vitro. Network pharmacology showed potential exosomes modulation of mJPYZ in gastric cancer. We extracted exosomes and found mJPYZ decreased the abundance of serum exosomes PKM2 in patients with advanced gastric cancer and xenograft tumor model. Additionally, we firstly detected and confirmed that PKM2 is a package protein of exosomes extracted from gastric cancer cells, and mJPYZ could diminish the content of exosomal PKM2 in gastric cancer cells. Importantly, mJPYZ reduced the delivery of exosomal PKM2 from tumor cells to macrophages, and alleviated exosomal PKM2-induced differentiation of M2-TAM in tumor microenvironment, eventually inhibited gastric cancer progression.
Gastric cancer exosomes containing PKM2 could lead to M2 macrophages differentiation, thereby promoting gastric cancer progression. Our findings provide a rationale for potential application of mJPYZ in the treatment of gastric cancer via PKM2.
改良健脾养正汤(mJPYZ)作为一种中医经验方,已被证明能显著延长晚期胃癌患者的生存时间。丙酮酸激酶 M2(PKM2)因其在细胞有氧糖酵解中的重要作用而备受关注,然而,很少有研究关注 PKM2 在肿瘤进展中的非代谢作用。
本研究旨在探讨含有 PKM2 的胃癌细胞外体在调节肿瘤相关巨噬细胞(TAM)中的作用及其 mJPYZ 抗胃癌的机制。
采用集落形成实验、流式细胞术和 TUNEL 染色法评估 mJPYZ 对荷瘤小鼠和细胞中胃癌的影响。Western blot 分析凋亡相关蛋白表达变化。网络药理学和生物信息学预测 mJPYZ 对胃癌的潜在外体调节作用。分离外体并与 TAM 共培养。用 Diff-Quik 染色观察外体孵育后 TAM 形态变化。采用流式细胞术和免疫荧光法检测外体 PKM2 是否参与 TAM 极化。
mJPYZ 通过靶向 PKM2 并下调体内和体外 PI3K/Akt/mTOR 轴,诱导胃癌细胞凋亡。网络药理学显示 mJPYZ 对胃癌的潜在外体调节作用。我们提取了外体,发现 mJPYZ 降低了晚期胃癌患者和异种移植肿瘤模型血清外体 PKM2 的丰度。此外,我们首次检测并证实 PKM2 是从胃癌细胞中提取的外体的包装蛋白,mJPYZ 可减少胃癌细胞中外体 PKM2 的含量。重要的是,mJPYZ 减少了肿瘤细胞中外泌体 PKM2 向巨噬细胞的传递,并减轻了外泌体 PKM2 在肿瘤微环境中诱导的 M2-TAM 分化,最终抑制了胃癌的进展。
含有 PKM2 的胃癌细胞外体可导致 M2 巨噬细胞分化,从而促进胃癌的进展。我们的研究结果为 mJPYZ 通过 PKM2 治疗胃癌提供了潜在的应用依据。